Net Income (Loss) Attributable to Parent in USD of Propanc Biopharma, Inc. from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Propanc Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2010 to Q3 2025.
  • Propanc Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$4.84M, a 1265% decline year-over-year.
  • Propanc Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$63.4M, a 3376% decline year-over-year.
  • Propanc Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2025 was -$58.9M, a 3137% decline from 2024.
  • Propanc Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$1.82M, a 31.6% increase from 2023.
  • Propanc Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$2.66M, a 0.09% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Propanc Biopharma, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$63.4M -$4.84M -$4.48M -1265% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$58.9M -$4.07M -$3.71M -1035% 01 Apr 2025 30 Jun 2025 10-K 29 Sep 2025
Q1 2025 -$55.2M -$54.1M -$53.5M -10165% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$1.67M -$430K +$154K +26.4% 01 Oct 2024 31 Dec 2024 10-Q 15 May 2025
Q3 2024 -$1.82M -$354K -$3.44K -0.98% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$1.82M -$359K +$389K +52.1% 01 Apr 2024 30 Jun 2024 10-K 29 Sep 2025
Q1 2024 -$2.21M -$527K +$283K +35% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$2.49M -$584K -$99K -20.4% 01 Oct 2023 31 Dec 2023 10-Q 15 May 2025
Q3 2023 -$2.39M -$351K +$266K +43.2% 01 Jul 2023 30 Sep 2023 10-Q 15 May 2025
Q2 2023 -$2.66M -$748K +$157K +17.3% 01 Apr 2023 30 Jun 2023 10-K 30 Sep 2024
Q1 2023 -$2.82M -$810K -$347K -75% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 -$2.47M -$485K +$315K +39.3% 01 Oct 2022 31 Dec 2022 10-Q 15 May 2024
Q3 2022 -$2.78M -$617K -$127K -25.8% 01 Jul 2022 30 Sep 2022 10-Q 15 May 2024
Q2 2022 -$2.66M -$905K -$126K -16.1% 01 Apr 2022 30 Jun 2022 10-K 28 Sep 2023
Q1 2022 -$2.53M -$463K -$44.9K -10.8% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$2.49M -$800K -$396K -98.2% 01 Oct 2021 31 Dec 2021 10-Q 15 May 2023
Q3 2021 -$2.09M -$491K -$65.1K -15.3% 01 Jul 2021 30 Sep 2021 10-Q 15 May 2023
Q2 2021 -$2.03M -$779K -$1.98M -165% 01 Apr 2021 30 Jun 2021 10-K 28 Sep 2022
Q1 2021 -$42.9K -$418K +$2.17M +83.8% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q4 2020 -$2.21M -$404K +$1.46M +78.4% 01 Oct 2020 31 Dec 2020 10-Q 16 May 2022
Q3 2020 -$3.67M -$426K +$1.07M +71.5% 01 Jul 2020 30 Sep 2020 10-Q 16 May 2022
Q2 2020 -$4.74M $1.2M +$2.81M 01 Apr 2020 30 Jun 2020 10-K 28 Sep 2021
Q1 2020 -$7.55M -$2.59M -$2M -344% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021
Q4 2019 -$5.54M -$1.87M -$417K -28.8% 01 Oct 2019 31 Dec 2019 10-Q 14 May 2021
Q3 2019 -$5.13M -$1.49M +$633K +29.8% 01 Jul 2019 30 Sep 2019 10-Q 14 May 2021
Q2 2019 -$5.76M -$1.6M -$179K -12.6% 01 Apr 2019 30 Jun 2019 10-K 01 Oct 2020
Q1 2019 -$5.58M -$582K +$909K +61% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q4 2018 -$6.49M -$1.45M +$752K +34.1% 01 Oct 2018 31 Dec 2018 10-Q 15 May 2020
Q3 2018 -$7.24M -$2.12M -$201K -10.5% 01 Jul 2018 30 Sep 2018 10-Q 15 May 2020
Q2 2018 -$7.04M -$1.42M +$211K +12.9% 01 Apr 2018 30 Jun 2018 10-K 15 Oct 2019
Q1 2018 -$7.25M -$1.49M -$120K -8.74% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019
Q4 2017 -$7.13M -$2.2M +$1.56M +41.5% 01 Oct 2017 31 Dec 2017 10-Q 15 May 2019
Q3 2017 -$8.69M -$1.92M -$822K -74.6% 01 Jul 2017 30 Sep 2017 10-Q 15 May 2019
Q2 2017 -$7.87M -$1.63M +$1.22M +42.8% 01 Apr 2017 30 Jun 2017 10-K 17 Sep 2018
Q1 2017 -$9.09M -$1.37M +$781K +36.3% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018
Q4 2016 -$9.87M -$3.76M -$199K -5.58% 01 Oct 2016 31 Dec 2016 10-Q 09 Feb 2018
Q3 2016 -$9.67M -$1.1M -$263K -31.4% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 -$9.41M -$2.86M -$1.03M -56.2% 01 Apr 2016 30 Jun 2016 10-K 28 Sep 2017
Q1 2016 -$8.38M -$2.15M -$1.7M -374% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017
Q4 2015 -$6.68M -$3.56M -$3.22M -931% 01 Oct 2015 31 Dec 2015 10-Q 14 Feb 2017
Q3 2015 -$3.47M -$839K -$55.6K -7.1% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016
Q2 2015 -$3.41M -$1.83M -$1.61M -741% 01 Apr 2015 30 Jun 2015 10-K 28 Sep 2016
Q1 2015 -$1.8M -$454K -$387K -579% 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016
Q4 2014 -$1.41M -$345K -$372K -1409% 01 Oct 2014 31 Dec 2014 10-Q 16 Feb 2016
Q3 2014 -$1.04M -$783K -$212K -37.1% 01 Jul 2014 30 Sep 2014 10-Q 16 Nov 2015
Q2 2014 -$830K -$218K +$6.95K +3.09% 01 Apr 2014 30 Jun 2014 10-K 30 Sep 2015
Q1 2014 -$837K -$66.9K +$271K +80.2% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015
Q4 2013 -$1.11M $26.4K +$414K 01 Oct 2013 31 Dec 2013 10-Q 17 Feb 2015
Q3 2013 -$1.52M -$572K -$78.8K -16% 01 Jul 2013 30 Sep 2013 10-Q 19 Nov 2014
Q2 2013 -$1.44M -$225K +$2.33M +91.2% 01 Apr 2013 30 Jun 2013 10-K 14 Oct 2014
Q1 2013 -$3.77M -$338K +$2.76M +89.1% 01 Jan 2013 31 Mar 2013 10-Q 20 May 2014
Q4 2012 -$6.53M -$388K +$2.32M +85.7% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014
Q3 2012 -$8.85M -$493K +$2.58M +84% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013
Q2 2012 -$11.4M -$2.55M 01 Apr 2012 30 Jun 2012 10-K 15 Oct 2013
Q1 2012 -$3.1M -$2.59M -509% 01 Jan 2012 31 Mar 2012 10-Q 20 May 2013
Q4 2011 -$2.71M -$2.3M -559% 01 Oct 2011 31 Dec 2011 10-Q 20 Feb 2013
Q3 2011 -$3.07M 01 Jul 2011 30 Sep 2011 10-Q 19 Nov 2012
Q1 2011 -$508K 01 Jan 2011 31 Mar 2011 10-Q 21 May 2012
Q4 2010 -$411K 01 Oct 2010 31 Dec 2010 10-Q/A 07 Mar 2012

Propanc Biopharma, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 -$58.9M -$57.1M -3137% 01 Jul 2024 30 Jun 2025 10-K 29 Sep 2025
2024 -$1.82M +$840K +31.6% 01 Jul 2023 30 Jun 2024 10-K 29 Sep 2025
2023 -$2.66M -$2.48K -0.09% 01 Jul 2022 30 Jun 2023 10-K 30 Sep 2024
2022 -$2.66M -$632K -31.2% 01 Jul 2021 30 Jun 2022 10-K 28 Sep 2023
2021 -$2.03M +$2.71M +57.3% 01 Jul 2020 30 Jun 2021 10-K 28 Sep 2022
2020 -$4.74M +$1.02M +17.7% 01 Jul 2019 30 Jun 2020 10-K 28 Sep 2021
2019 -$5.76M +$1.28M +18.2% 01 Jul 2018 30 Jun 2019 10-K 01 Oct 2020
2018 -$7.04M +$828K +10.5% 01 Jul 2017 30 Jun 2018 10-K 15 Oct 2019
2017 -$7.87M +$1.54M +16.4% 01 Jul 2016 30 Jun 2017 10-K 17 Sep 2018
2016 -$9.41M -$6M -176% 01 Jul 2015 30 Jun 2016 10-K 28 Sep 2017
2015 -$3.41M -$2.58M -311% 01 Jul 2014 30 Jun 2015 10-K 28 Sep 2016
2014 -$830K +$613K +42.5% 01 Jul 2013 30 Jun 2014 10-K 30 Sep 2015
2013 -$1.44M +$9.99M +87.4% 01 Jul 2012 30 Jun 2013 10-K 14 Oct 2014
2012 -$11.4M -$9.28M -431% 01 Jul 2011 30 Jun 2012 10-K 15 Oct 2013
2011 -$2.15M -$1.31M -155% 01 Jul 2010 30 Jun 2011 10-K 15 Oct 2013
2010 -$842K 01 Jul 2009 30 Jun 2010 10-K 15 Oct 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.